Boston Scientific Research and development expense decreased by 9.3% to $516.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.5%, from $443.00M to $516.00M. Over 4 years (FY 2021 to FY 2025), Research and development expense shows an upward trend with a 14.3% CAGR.
Higher spending typically signals a commitment to long-term innovation and future product pipelines, while significant cuts may signal a shift toward short-term profitability.
This metric captures the investment in creating new products, improving existing technologies, and advancing internal ca...
Standard metric for technology and hardware firms; highly comparable to R&D spending at peers.
other_research_and_development_expense_excluding_acquire_88a3cd| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $298.00M | $310.00M | $320.00M | $319.00M | $335.00M | $339.00M | $330.00M | $337.00M | $359.00M | $356.00M | $363.00M | $366.00M | $383.00M | $407.00M | $459.00M | $443.00M | $526.00M | $514.00M | $569.00M | $516.00M |
| QoQ Change | — | +4.0% | +3.2% | -0.3% | +5.0% | +1.2% | -2.7% | +2.1% | +6.5% | -0.8% | +2.0% | +0.8% | +4.6% | +6.3% | +12.8% | -3.5% | +18.7% | -2.3% | +10.7% | -9.3% |
| YoY Change | — | — | — | — | +12.4% | +9.4% | +3.1% | +5.6% | +7.2% | +5.0% | +10.0% | +8.6% | +6.7% | +14.3% | +26.4% | +21.0% | +37.3% | +26.3% | +24.0% | +16.5% |